USFDA completes inspection at Laurus Labs’ API facilities in Visakhapatnam
14th Jun 2019

US Food and Drug Administration (USFDA) has completed inspection at Laurus Labs’ API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature. This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.